SODIUM NITROPRUSSIDE (sodium nitroprusside) by Baxter International is clinical pharmacology the principal pharmacological action of sodium nitroprusside is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins. Approved for acute congestive heart failure. First approved in 1982.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Sodium nitroprusside is a rapid-acting vasodilator administered intravenously that relaxes vascular smooth muscle in both arteries and veins. It is indicated for acute congestive heart failure and hypertensive crises, working by reducing preload and afterload through peripheral vasodilation with a circulatory half-life of approximately 2 minutes.
As a legacy product approaching loss of exclusivity, the brand team is likely small and focused on defending market position against established generic and branded competitors in the acute care segment.
CLINICAL PHARMACOLOGY The principal pharmacological action of sodium nitroprusside is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins. Other smooth muscle (e.g., uterus, duodenum) is not affected. Sodium nitroprusside is more active on veins than on…
Worked on SODIUM NITROPRUSSIDE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on sodium nitroprusside offers limited career growth due to the product's mature lifecycle and approaching loss of exclusivity, with most opportunities concentrated in hospital-based sales, formulary defense, and cost-based account management. Positions are likely stable but modest in number and advancement potential, making this suitable for specialists in acute care or hospital commercial roles rather than dynamic career launches.